Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 34

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 34
---
 Effective March 1, 2024, the annual base salary rates for our NEOs were $625,000 for Dr. Pfeiffenberger, $546,000 for Dr. Russotti and $516,400 for Dr. Farid.

Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 22

TABLE OF CONTENTS

| ​ | EXECUTIVE COMPENSATION | ​ |

Annual Incentive Opportunities Each of our NEO’s annual non-equity incentive opportunity is expressed as a percentage of base salary that can be earned based on the achievement of predetermined corporate and individual performance objectives. The 2024 annual bonus opportunities for Dr. Pfeiffenberger, Dr. Russotti and Dr. Farid were targeted at 55%, 45% and 40% of their respective base salaries. For 2024, all NEOs were eligible to earn their annual cash incentives pursuant to the achievement of corporate and/or individual performance goals approved by our Board. These goals primarily related to pipeline and platform development, manufacturing, business development and financing. The Board determined that the 2024 corporate goals were achieved at 105%. Following a review of 2024 performance, our Compensation Committee approved, and, in the case of Dr. Pfeiffenberger, our Compensation Committee recommended and our Board approved, 2024 annual cash incentive payouts to each of Dr. Pfeiffenberger, Dr. Russotti, and Dr. Farid equal to $360,938, $256,331 and $215,481, respectively, in each case representing 105% of the target cash incentive for each such NEO. In addition to his 2024 annual cash incentive, Dr. Pfeiffenberger received a one-time cash retention bonus of $450,000 in connection with the commencement of his employment. This retention bonus was paid in 2024 and was subject to repayment under certain termination scenarios, as described in the “Employee Agreements” section below. Long Term Equity Incentives Annual Equity Grants Our equity-based incentive awards are designed to align the interests of our stockholders with those of our NEOs. Our Board or Compensation Committee, as applicable, approves equity grants to NEOs under our 2021 Plan. In 2024, our Compensation Committee recommended and our Board approved, an equity grant to Dr. Pfeiffenberger of (i) an option to purchase 104,550 shares of common stock and (ii) 17,425 restricted stock units,